Loading financials from SEC filings…
Drug manufacturers · Healthcare · Fiscal year ends Dec 31
Immunome reported revenue of $7M in the fiscal year ended Dec 2025, down 23.2% from the year before. Operating income was −$224M, an operating margin of −3228.8%, and net income was −$212M. Operating cash flow of −$191M less capital expenditure of $10M left free cash flow of −$201M.
Ranks among the 78 drug manufacturers companies we cover (1st = best; for debt, the least indebted). Green = top third, red = bottom third.
Last 5 fiscal years
| Fiscal year | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Revenue | – | – | 14.0 | 9.0 | 6.9 |
| Research & development | 14.1 | 23.3 | 23.1 | 130 | 177 |
| Operating income | −25.2 | −36.9 | −110 | −306 | −224 |
| Net interest incomeBanks | −0.0 | 0.0 | 2.7 | 12.8 | 11.7 |
| Income tax | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Net income | −24.7 | −36.9 | −107 | −293 | −212 |
| Diluted EPS | −2.14 | −3.09 | −5.38 | −5.00 | −2.43 |
| Diluted shares | 11.5 | 12.1 | 19.8 | 58.6 | 87.4 |
| Fiscal year | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Cash & equivalents | 49.2 | 20.3 | 98.7 | 143 | 653 |
| Current assets | 56.6 | 22.6 | 145 | 221 | 661 |
| Net PP&E | 0.9 | 0.7 | 2.1 | 10.1 | 14.6 |
| Total assets | 57.9 | 24.0 | 149 | 240 | 683 |
| Payables | 3.1 | 2.4 | 3.3 | 14.2 | 3.3 |
| Deferred revenue | – | – | 10.5 | 6.9 | 0.0 |
| Current liabilities | 9.7 | 7.3 | 21.8 | 54.3 | 45.0 |
| Total liabilities | 9.7 | 7.4 | 28.7 | 59.1 | 48.8 |
| Shareholders' equity | 48.2 | 16.7 | 120 | 181 | 634 |
| Fiscal year | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating cash flow | −18.2 | −28.7 | −7.6 | −111 | −191 |
| Capital expenditure | 0.1 | 0.2 | 0.8 | 7.2 | 9.7 |
| Free cash flow | −18.3 | −28.9 | −8.4 | −118 | −201 |
| Depreciation & amortisation | 0.8 | 0.4 | 0.5 | 1.6 | 2.5 |
| Stock-based compensation | 3.4 | 5.3 | 6.2 | 15.7 | 25.7 |
| Fiscal year | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Revenue growth (YoY) | – | – | – | −35.5% | −23.2% |
| Operating margin | – | – | −781.4% | −3382.4% | −3228.8% |
| Net margin | – | – | −761.9% | −3240.4% | −3060.0% |
| Return on equityBlank when equity is negative | −51.3% | −221.6% | −89.1% | −161.7% | −33.5% |
| ROCEEBIT ÷ (assets − current liabilities) | −52.3% | −220.8% | −86.4% | −164.5% | −35.1% |
| Free cash flow margin | – | – | −59.9% | −1304.8% | −2890.1% |
| Cash conversion (CFO ÷ net income) | 0.74x | 0.78x | 0.07x | 0.38x | 0.90x |
| Current ratio | 5.82x | 3.09x | 6.63x | 4.08x | 14.7x |
Standardised figures from the company's XBRL filings with the SEC (10-K, 10-Q). Line items follow US GAAP tags, so a company's own statement layout may differ and some lines show “–” where the company does not report that item. Ratios are calculated from these figures. For education only; not investment advice or a recommendation.